MedTrace Logo

Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma

NCT00869141 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2015-12-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the occurrence rate of the high pressure phase and the final pressure outcomes between patients treated with glaucoma medication prior to the expected onset of the high pressure phase to those patients who have glaucoma medication started at the onset of the high pressure phase. The investigators hypothesize that if glaucoma medications are started prior to the expected onset of high pressure phase, the high pressure phase will not occur as frequently and the ultimate pressure level will be lower than if the glaucoma medications are started at the onset of this phase.

Conditions

Interventions

DRUG

glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)

Subjects may receive glaucoma medications after Ahmed valve implantation

Sponsors & Collaborators

Principal Investigators

  • Simon K Law, MD · Jules Stein Eye Institute, University of California Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00869141 on ClinicalTrials.gov